Skye Bioscience Losses Widen Amid R&D Push

Ticker: SKYE · Form: 10-Q · Filed: Aug 7, 2025 · CIK: 1516551

Sentiment: bearish

Topics: Biotechnology, Pharmaceuticals, Clinical Trials, Net Loss, R&D Expenses, Glaucoma, Ophthalmic

Related Tickers: SKYE

TL;DR

SKYE is burning cash faster than ever with no revenue in sight; expect more dilution as they chase clinical trial success.

AI Summary

Skye Bioscience, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-revenue stage as a pharmaceutical company. The company's net loss for the three months ended June 30, 2025, was $6.15 million, a significant increase from a net loss of $4.03 million for the same period in 2024. For the six months ended June 30, 2025, the net loss was $12.30 million, up from $8.05 million in the prior year. This widening loss is primarily driven by increased research and development expenses as the company advances its drug candidates. Skye Bioscience continues to focus on its clinical trials, particularly for its lead drug candidate, SBI-100 Ophthalmic Emulsion, for glaucoma and ocular hypertension. The company's strategic outlook remains centered on progressing its pipeline through clinical development and securing additional financing to support these efforts, as evidenced by its reliance on equity financing and the absence of product sales.

Why It Matters

For investors, Skye Bioscience's increasing net losses of $6.15 million for Q2 2025 and $12.30 million for H1 2025 highlight the significant capital requirements of drug development, signaling continued dilution risk without near-term revenue. Employees face job security tied to successful clinical trials and ongoing funding. Customers, specifically patients with glaucoma and ocular hypertension, are awaiting potential new treatments, making the company's R&D progress critical. In the broader market, Skye's advancements or setbacks could influence investor sentiment towards other small-cap biotech firms in the ophthalmic space, especially those competing in the glaucoma treatment market.

Risk Assessment

Risk Level: high — The company reported a net loss of $6.15 million for the three months ended June 30, 2025, and $12.30 million for the six months ended June 30, 2025, with no revenue. This significant cash burn, coupled with the inherent uncertainties and high costs of pharmaceutical development, indicates a high financial risk. The company's ability to continue as a going concern is dependent on its ability to raise additional capital.

Analyst Insight

Investors should exercise extreme caution and consider this a highly speculative investment. Monitor the progress of SBI-100 Ophthalmic Emulsion clinical trials closely and assess the company's ability to secure additional financing, as further dilution is highly probable.

Financial Highlights

debt To Equity
N/A
revenue
$0
operating Margin
N/A
total Assets
N/A
total Debt
N/A
net Income
-$12.30M
eps
N/A
gross Margin
N/A
cash Position
N/A
revenue Growth
N/A

Revenue Breakdown

SegmentRevenueGrowth
Pharmaceuticals$0N/A

Key Numbers

Key Players & Entities

FAQ

What were Skye Bioscience's revenues for the second quarter of 2025?

Skye Bioscience, Inc. reported no revenue for the three months ended June 30, 2025, consistent with its status as a pre-revenue pharmaceutical company focused on drug development.

How much was Skye Bioscience's net loss for the first half of 2025?

For the six months ended June 30, 2025, Skye Bioscience, Inc. reported a net loss of $12.30 million, which is an increase from the $8.05 million net loss reported for the same period in 2024.

What is Skye Bioscience's primary drug candidate?

Skye Bioscience's primary drug candidate is SBI-100 Ophthalmic Emulsion, which is currently in clinical development for the treatment of glaucoma and ocular hypertension.

Why are Skye Bioscience's losses increasing?

Skye Bioscience's losses are increasing primarily due to higher research and development expenses as the company advances its drug candidates through clinical trials, a common characteristic of early-stage pharmaceutical companies.

What are the main risks for investors in Skye Bioscience?

The main risks for investors in Skye Bioscience include the significant and increasing net losses, the absence of revenue, the high costs and uncertainties associated with drug development, and the ongoing need to raise additional capital, which could lead to shareholder dilution.

How does Skye Bioscience plan to fund its operations?

Skye Bioscience plans to fund its operations primarily through equity financing, as indicated by its reliance on raising capital to support its research and development efforts and general corporate purposes.

What is the current stage of development for SBI-100 Ophthalmic Emulsion?

SBI-100 Ophthalmic Emulsion is currently in clinical development, with the company focused on progressing its clinical trials for glaucoma and ocular hypertension.

Has Skye Bioscience generated any revenue from product sales?

No, Skye Bioscience, Inc. has not generated any revenue from product sales for the three and six months ended June 30, 2025, as it is still in the development stage and has no approved products on the market.

What was the net loss for Skye Bioscience in Q2 2024?

For the three months ended June 30, 2024, Skye Bioscience, Inc. reported a net loss of $4.03 million, which increased to $6.15 million in Q2 2025.

What is the significance of the 10-Q filing date for Skye Bioscience?

The 10-Q filing date of August 7, 2025, for Skye Bioscience, Inc. indicates the company's compliance with SEC regulations to report its financial performance and operational status for the quarter ended June 30, 2025.

Risk Factors

Industry Context

Skye Bioscience operates in the highly competitive pharmaceutical and biotechnology sector, specifically focusing on ophthalmic treatments. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Success hinges on innovation, clinical trial outcomes, and the ability to navigate complex approval processes.

Regulatory Implications

As a pre-revenue biopharmaceutical company, Skye Bioscience faces substantial regulatory risks. The progression of its drug candidates, particularly SBI-100 Ophthalmic Emulsion, through clinical trials and subsequent FDA approval is critical. Any delays, adverse findings, or failure to meet regulatory standards could severely impact the company's future prospects.

What Investors Should Do

  1. Monitor clinical trial progress and regulatory updates for SBI-100 Ophthalmic Emulsion.
  2. Assess the company's cash burn rate and future financing needs.
  3. Evaluate the competitive landscape for glaucoma and ocular hypertension treatments.

Glossary

10-Q
A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document is the 10-Q filing for Skye Bioscience, Inc., providing the latest financial and operational details.)
SBI-100 Ophthalmic Emulsion
A specific drug candidate being developed by Skye Bioscience. (This is the company's lead drug candidate, currently in clinical trials for glaucoma and ocular hypertension, representing a key focus of R&D efforts.)
Pre-revenue stage
A phase in a company's lifecycle where it has not yet generated any sales revenue from its products or services. (Skye Bioscience is in this stage, meaning its financial performance is characterized by expenses related to development rather than income from sales.)
Net Loss
The total expenses of a company exceed its total revenues over a specific period. (Skye Bioscience reported significant net losses, indicating that its operating and development costs are currently higher than any potential revenue streams.)

Year-Over-Year Comparison

Skye Bioscience reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-revenue status. However, the company's net loss has widened significantly compared to the prior year, with Q2 2025 losses at $6.15 million versus $4.03 million in Q2 2024, and H1 2025 losses at $12.30 million versus $8.05 million in H1 2024. This increase is attributed to higher research and development expenses as the company advances its drug pipeline.

Filing Stats: 4,527 words · 18 min read · ~15 pages · Grade level 13.1 · Accepted 2025-08-07 16:04:10

Key Financial Figures

Filing Documents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements: 2 Condensed Consolidated Balance Sheets as of June 30, 2025 (Unaudited) and December 31, 2024 2 Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2025 and 2024 (Unaudited) 4 Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024 (Unaudited) 5 Condensed Consolidated Statements of Stockholders' Equity for the Three and Six Months Ended June 30, 2025 and 2024 (Unaudited) 6 Notes to the Unaudited Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 15 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 22 Item 4.

Controls and Procedures

Controls and Procedures 22

- OTHER INFORMATION

PART II - OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 23 Item 1A.

Risk Factors

Risk Factors 23 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 23 Item 3. Defaults Upon Senior Securities 23 Item 4. Mine Safety Disclosures 23 Item 5. Other Information 23 Item 6. Exhibits 24

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements 2 SKYE BIOSCIENCE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS June 30, 2025 December 31, 2024 (Unaudited) ASSETS Current assets Cash and cash equivalents $ 23,838,244 $ 68,415,741 Short-term investments 24,747,039 — Prepaid expenses 1,263,812 201,962 Other current assets 733,423 2,209,544 Total current assets 50,582,518 70,827,247 Property and equipment, net 1,169,056 1,432,752 Operating lease right-of-use asset 355,427 449,864 Other assets 53,910 53,910 Total assets $ 52,160,911 $ 72,763,773 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 3,222,510 $ 569,252 Accrued payroll liabilities 868,024 1,114,255 Other current liabilities 2,220,063 654,201 Estimate for accrued legal contingencies and related expenses 1,806,065 1,818,751 Operating lease liability, current portion 195,046 182,428 Total current liabilities 8,311,708 4,338,887 Non-current liabilities Operating lease liability, net of current portion 172,494 273,162 Total liabilities 8,484,202 4,612,049 Commitments and contingencies (Note 7) Stockholders' equity Preferred stock, $ 0.001 par value; 200,000 shares authorized at June 30, 2025 and December 31, 2024; no shares issued and outstanding at June 30, 2025 and December 31, 2024 — — Common stock, $ 0.001 par value; 100,000,000 shares authorized at June 30, 2025 and December 31, 2024; 30,988,108 and 30,974,559 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 30,988 30,975 Additional paid-in-capital 203,323,584 199,070,421 Accumulated deficit ( 159,677,863 ) ( 130,949,672 ) Total stockholders' equity 43,676,709 68,151,724 Total liabilities and stockholders' equity $ 52,160,911 $ 72,763,773 See accompanying notes to the unaudited condensed consolidated financial statements. 3 SKYE BIOSCIENCE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Three Months Ended June 30,

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing